key: cord-0814099-qfcfm40m authors: Giannini, Margherita; Ohana, Mickael; Nespola, Benoit; Zanframundo, Giovanni; Geny, Bernard; Meyer, Alain title: Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? date: 2020-07-06 journal: Eur Respir J DOI: 10.1183/13993003.01618-2020 sha: de2d049a0093276a03b5b715fc48c0f8c36f6162 doc_id: 814099 cord_uid: qfcfm40m Since the end of 2019, the coronavirus disease 2019 (COVID-19) pandemic has struck worldwide, leading to more than 7 million cases by June 2020, with an approximately 5.5% mortality rate, mainly due to acute respiratory distress syndrome (ARDS) [1]. Since the end of 2019, the coronavirus disease 2019 (COVID-19) pandemic has struck worldwide, leading to more than 7 million cases by June 2020, with an approximately 5.5% mortality rate, mainly due to acute respiratory distress syndrome (ARDS). 1 Current conventional treatment is mainly based on support therapy and there is an urgent need for effective, specific treatments. Currently, no direct-acting antiviral drugs have demonstrated efficacy in the disease. Contrariwise, increasing evidence indicates an immune-mediated pathophysiology that is paving the way for the evaluation of immunomodulation strategies. 2 Supporting this view, we would like to highlight the striking similarities between COVID-19 and a rare autoimmune disease: the anti-MDA5-syndrome. The hallmark of this disease is the presence of auto-antibodies targeting MDA5, an intracellular sensor of viral RNA (including coronavirus) that triggers the innate immune response. 3 The syndrome is characterized by systemic signs resembling COVID-19, and ARDS is the main cause of death ( Figure 1A ). 4, 5 In addition, chest computed tomography findings, 6 COVID-19) situation report -106 COVID-19: consider cytokine storm syndromes and immunosuppression A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis Clinical management of COVID-19. Interim guidance Coronavirus breakthrough: dexamethasone is first drug shown to save lives Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 Alain Meyer: no disclosures. Funding: none. Aknowledgments: we thank Mrs Pragnell Babette for her English support. Authors contributions Margherita Giannini: literature search, figures, study design, data collection, data analysis, data interpretation, writing. Mickael Ohana: figures, data collection, data interpretation Giovanni Zanframundo: data interpretation. Bernard Geny: data interpretation, writing Alain Meyer: literature search, figures, study design, data collection, data analysis, data interpretation, writing